NeuroVive Pharmaceutical AB (publ) today announced that 22 January 2014 is the last day of trading in subscription rights in the company's ongoing new issue. The subscription period will continue unti ...

On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majori ...

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from ...

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company ́s drug candidate NeuroSTAT® for the ...